Literature DB >> 5005303

Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. I. Interaction between immunoglobulins, heat-labile serum factors, and phagocytic cells in the killing of bacteria.

A B Bjornson, J G Michael.   

Abstract

Techniques have been described for the purification of mouse polymorphonuclear leukocytes (PMN) and macrophages and for determining their bactericidal activity against Pseudomonas aeruginosa in a rotating suspension. Requirements for human anti-Pseudomonas opsonins and heat-labile mouse serum factors have been determined. In the macrophage system, although heat-labile mouse serum factors had enhancing properties, both immunoglobulin G (IgG) and immunoglobulin M (IgM) opsonins alone sufficed to induce bactericidal activity. In contrast, both opsonins and heat-labile mouse serum factors were required for bactericidal activity by the mouse PMN. In the absence of heat-labile mouse serum factors, IgG and IgM opsonins contributed to the bactericidal activity of mouse macrophages to the same extent. However, in the presence of these factors, much less IgG than IgM antibody was required to achieve maximum bactericidal activity by these cells. Similarly, IgG opsonins were found to be more efficient than IgM opsonins in enhancing the killing of P. aeruginosa by mouse PMN.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5005303      PMCID: PMC416332          DOI: 10.1128/iai.4.4.462-467.1971

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Studies on the immunoglobulins which stimulate the ingestion of glutaraldehyde-treated red cells attached to macrophages.

Authors:  M Rabinovitch
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

2.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

3.  Opsonic, cytophilic and agglutinating activity of guinea-pig gamma-2 and gamma-M anti-Salmonella antibodies.

Authors:  P Del Guercio; G Tolone; F B Andrade; G Biozzi; R A Binaghi
Journal:  Immunology       Date:  1969-03       Impact factor: 7.397

4.  Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes.

Authors:  S J Klebanoff
Journal:  Science       Date:  1970-09-11       Impact factor: 47.728

5.  Metabolic event involved in the bactericidal activity of normal mouse macrophages.

Authors:  T E Miller
Journal:  Infect Immun       Date:  1971-03       Impact factor: 3.441

6.  The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors.

Authors:  R B Johnston; M R Klemperer; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

7.  THE IN VITRO DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. II. THE INFLUENCE OF SERUM ON GRANULE FORMATION, HYDROLASE PRODUCTION, AND PINOCYTOSIS.

Authors:  Z A COHN; B BENSON
Journal:  J Exp Med       Date:  1965-05-01       Impact factor: 14.307

8.  Interactions between rabbit polymorphonuclear leucocytes and staphylococci.

Authors:  Z A COHN; S I MORSE
Journal:  J Exp Med       Date:  1959-09-01       Impact factor: 14.307

9.  The fate of bacteria within phagocytic cells. I. The degradation of isotopically labeled bacteria by polymorphonuclear leucocytes and macrophages.

Authors:  Z A COHN
Journal:  J Exp Med       Date:  1963-01-01       Impact factor: 14.307

10.  Receptors for complement of leukocytes.

Authors:  W H Lay; V Nussenzweig
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  22 in total

1.  Mechanisms of immunity in typhus infections. 3. Influence of human immune serum and complement on the fate of Rickettsia mooseri within the human macrophages.

Authors:  M R Gambrill; C L Wisseman
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

2.  Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice.

Authors:  G C Tsay; M S Collins
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

3.  Opsonins in normal mouse serum for the phagocytic killing of Proteus mirabilis by murine neutrophils.

Authors:  J J Finlay-Jones; N L Hill; M F Nulsen; H Pruul; P J McDonald
Journal:  Br J Exp Pathol       Date:  1984-12

4.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

5.  Passive immunity against pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen; H J Amirault
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

6.  Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

7.  Characterization of opsonins for Bacteroides fragilis in immune sera collected from experimentally infected mice.

Authors:  T M Ellis; J T Barrett
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

8.  Effects of AC-1370, a new semisynthetic cephalosporin, on phagocyte functions.

Authors:  H Ohnishi; H Kosuzume; H Inaba; M Okura; H Mochizuki; Y Suzuki; R Fujii
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

9.  Serological and biological activities of anti-Haemophilus influenzae ribosomal serum.

Authors:  M Katz; M Lynn; M Solotorovsky
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

10.  Protective effects of S-sulfonated human gamma globulin against experimental infections in mice.

Authors:  H Tomioka; Y Iwamura; Y Suzuki; S Ohtomo; Y Hashimoto
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.